title: Efficacy of an angiotensin II receptor antagonist in managing hyperaldosteronism.
abstract: OBJECTIVE
  To determine whether an angiotensin II receptor antagonist decreases blood pressure in patients with hyperaldosteronism and hypertension who are taking other antihypertensive agents.
  
  
  METHODS
  A double-blind randomized placebo-controlled crossover study.
  
  
  METHODS
  Blood pressure and hormonal responses to 2-week courses of placebo/irbesartan (150 mg/day given by mouth at 08.05 h) were assessed in 10 patients with hyperaldosteronism. Clinic blood pressure was measured by sphygmomanometer, and plasma concentrations of aldosterone, cortisol, angiotensin II, electrolytes and renin activity (PRA) were determined weekly. Automated 24 h ambulatory blood pressure recordings were made at the end of the active and placebo phases.
  
  
  RESULTS
  Irbesartan caused a post-dose decrease in ambulatory blood pressure (systolic, P = 0.02; diastolic, P = 0.05) in the period from 10.00 h to 20.00 h. Clinic blood pressure, measured at trough, was not significantly decreased. Plasma aldosterone decreased (P < 0.03) and PRA increased (P < 0.04) in the first week of active treatment with irbesartan, but differences between the placebo and active-treatment groups were not significant in the second week. There were no significant changes in plasma concentrations of angiotensin II, cortisol or potassium in either week. In the second week of irbesartan treatment, there were associations between change in plasma aldosterone and maximal change in ambulatory blood pressure (systolic and diastolic).
  
  
  CONCLUSIONS
  Irbesartan has a role in combination antihypertensive treatment of patients with hyperaldosteronism.
authors.affiliation: Department of Cardiology, Royal North Shore Hospital, St Leonards, NSW, Australia. gstokes@med.usyd.edu.au
authors.forename: G S
authors.initials: GS
authors.lastname: Stokes
authors.forename: J C
authors.initials: JC
authors.lastname: Monaghan
authors.forename: M
authors.initials: M
authors.lastname: Ryan
authors.forename: M
authors.initials: M
authors.lastname: Woodward
mesh_terms: D000328:Adult; D000368:Aged; D000450:Aldosterone / Q000097:blood; D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006929:Hyperaldosteronism / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D000077405:Irbesartan; D008297:Male; D008875:Middle Aged; D012083:Renin / Q000097:blood; D013777:Tetrazoles / Q000627:therapeutic use*
chemical_list: D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D013777:Tetrazoles; D000450:Aldosterone; D012083:Renin; D000077405:Irbesartan